Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
J Med Chem
; 51(6): 1668-80, 2008 Mar 27.
Article
in En
| MEDLINE
| ID: mdl-18324759
ABSTRACT
We have previously shown N-arylnaphthamides can be potent inhibitors of vascular endothelial growth factor receptors (VEGFRs). N-Alkyl and N-unsubstituted naphthamides were prepared and found to yield nanomolar inhibitors of VEGFR-2 (KDR) with an improved selectivity profile against a panel of tyrosine and serine/threonine kinases. The inhibitory activity of this series was retained at the cellular level. Naphthamides 3, 20, and 22 exhibited good pharmacokinetics following oral dosing and showed potent inhibition of VEGF-induced angiogenesis in the rat corneal model. Once-daily oral administration of 22 for 14 days led to 85% inhibition of established HT29 colon cancer and Calu-6 lung cancer xenografts at doses of 10 and 20 mg/kg, respectively.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vascular Endothelial Growth Factor Receptor-2
/
Endothelial Cells
/
Protein Kinase Inhibitors
/
Naphthalenes
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Language:
En
Journal:
J Med Chem
Journal subject:
QUIMICA
Year:
2008
Type:
Article
Affiliation country:
United States